| Project/Area Number |
16209034
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
NIITSU Yoshiro Sapporo Medical University, Fourth Department of Internal Medicine, Professor, 医学部, 教授 (10045502)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAMADA Hirofumi Sapporo Medical University, Department of Molecular Medicine, Professor, 医学部, 教授 (00189614)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥49,920,000 (Direct Cost: ¥38,400,000、Indirect Cost: ¥11,520,000)
Fiscal Year 2006: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2005: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2004: ¥20,670,000 (Direct Cost: ¥15,900,000、Indirect Cost: ¥4,770,000)
|
|---|
| Keywords | AML / VLA4 / Humanized chimeric antibodies / 急性白血病 / キメラ抗体 |
|---|
| Research Abstract |
We collected the leukemic cells from 82 acute myelogenous leukemia (AML) patients via departments of hematology in medical university hospitals, and measured the expression of VLA4 on AML cells by FACS. We are analyzing a relationship between the intensities of VLA4 expressions and prognoses of AML patients. Simultaneously, we succeeded to produce humanized chimeric anti-VLA4 antibodies using gene recombination techniques. Furthermore, we confirmed that the effects of combination therapy using humanized chimeric anti-VLA4 antibodies and anti-cancer drag was superior to that of treatment by anti-cancer drug alone in vitro and in vivo (AML model mice : human AML minimal residual disease model mice, human AML model mice at diagnosis or at relapse). We will study the safety, pharmacokinetics and pharmacodynamics of humanized chimeric anti-VLA4 antibodies by administration to the monkeys, and perform the translational research.
|
